Jennifer Lachey's most recent trade in Keros Therapeutics Inc was a trade of 46,034 Common Stock done at an average price of $30 . Disclosure was reported to the exchange on July 15, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 15 Jul 2022 | 46,034 | 95,100 | - | 30 | 1,381,020 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 46,034 | 8,755 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 15 Jul 2022 | 46,034 | 141,134 | - | 0.3 | 13,810 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 13 Jul 2022 | 1,916 | 95,100 | - | 30 | 57,480 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,916 | 54,789 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 13 Jul 2022 | 1,916 | 93,184 | - | 0.3 | 575 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 9,400 | 56,705 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 14 Jun 2022 | 9,400 | 95,100 | - | 0.3 | 2,820 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 11 May 2022 | 5,300 | 91,000 | - | 0.3 | 1,590 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2022 | 5,300 | 66,105 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.26 per share. | 11 May 2022 | 3,398 | 87,602 | - | 41.3 | 140,201 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 42.49 per share. | 11 May 2022 | 944 | 86,658 | - | 42.5 | 40,111 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 43.32 per share. | 11 May 2022 | 719 | 85,939 | - | 43.3 | 31,147 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 44.23 per share. | 11 May 2022 | 223 | 85,716 | - | 44.2 | 9,863 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 45.44 per share. | 11 May 2022 | 16 | 85,700 | - | 45.4 | 727 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 11 Apr 2022 | 5,300 | 91,000 | - | 0.3 | 1,590 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2022 | 5,300 | 71,405 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 63.50 per share. | 11 Apr 2022 | 2,315 | 86,259 | - | 63.5 | 147,003 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 61.37 per share. | 11 Apr 2022 | 1,417 | 89,583 | - | 61.4 | 86,961 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 62.32 per share. | 11 Apr 2022 | 1,009 | 88,574 | - | 62.3 | 62,881 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 64.15 per share. | 11 Apr 2022 | 559 | 85,700 | - | 64.2 | 35,860 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 04 Apr 2022 | 7,950 | 85,700 | - | 60 | 477,000 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2022 | 7,950 | 76,705 | - | - | of Shares Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 04 Apr 2022 | 7,950 | 93,650 | - | 0.3 | 2,385 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 11 Mar 2022 | 2,650 | 88,350 | - | 0.3 | 795 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2022 | 2,650 | 84,655 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 52.43 per share. | 11 Mar 2022 | 1,062 | 87,288 | - | 52.4 | 55,681 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 54.54 per share. | 11 Mar 2022 | 875 | 85,700 | - | 54.5 | 47,723 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 53.36 per share. | 11 Mar 2022 | 713 | 86,575 | - | 53.4 | 38,046 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 2,650 | 87,305 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 11 Feb 2022 | 2,650 | 88,350 | - | 0.3 | 795 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 52.35 per share. | 11 Feb 2022 | 1,378 | 85,899 | - | 52.3 | 72,138 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 51.50 per share. | 11 Feb 2022 | 1,073 | 87,277 | - | 51.5 | 55,260 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 53.10 per share. | 11 Feb 2022 | 199 | 85,700 | - | 53.1 | 10,567 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 50,000 | 50,000 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2022 | 2,650 | 89,955 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 11 Jan 2022 | 2,650 | 88,350 | - | 0.3 | 795 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 53.56 per share. | 11 Jan 2022 | 1,196 | 86,834 | - | 53.6 | 64,058 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 54.45 per share. | 11 Jan 2022 | 1,134 | 85,700 | - | 54.4 | 61,746 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 52.01 per share. | 11 Jan 2022 | 320 | 88,030 | - | 52.0 | 16,643 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 05 Jan 2022 | 2,650 | 85,700 | - | 60 | 159,000 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2022 | 2,650 | 92,605 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 05 Jan 2022 | 2,650 | 88,350 | - | 0.3 | 795 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 13 Dec 2021 | 1,915 | 87,615 | - | 0.3 | 575 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2021 | 1,915 | 95,990 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 50.11 per share. | 13 Dec 2021 | 1,518 | 86,097 | - | 50.1 | 76,067 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2021 | 735 | 95,255 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 13 Dec 2021 | 735 | 85,700 | - | 50 | 36,750 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 13 Dec 2021 | 735 | 86,435 | - | 0.3 | 221 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 52.22 per share. | 13 Dec 2021 | 390 | 85,707 | - | 52.2 | 20,366 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 53.57 per share. | 13 Dec 2021 | 7 | 85,700 | - | 53.6 | 375 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 10 Nov 2021 | 15,900 | 85,700 | - | 60 | 954,000 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2021 | 15,900 | 103,205 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 10 Nov 2021 | 15,900 | 101,600 | - | 0.3 | 4,770 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2021 | 5,300 | 97,905 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 10 Nov 2021 | 5,300 | 91,000 | - | 0.3 | 1,590 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 59.78 per share. | 10 Nov 2021 | 4,561 | 85,700 | - | 59.8 | 272,657 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 58.73 per share. | 10 Nov 2021 | 739 | 90,261 | - | 58.7 | 43,401 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 04 Nov 2021 | 10,600 | 85,700 | - | 50 | 530,000 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2021 | 10,600 | 119,105 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 04 Nov 2021 | 10,600 | 96,300 | - | 0.3 | 3,180 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 1,293 | 0 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 17 Aug 2021 | 1,293 | 85,700 | - | 0.3 | 388 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2021 | 6,500 | 1,293 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 24 Jun 2021 | 6,500 | 84,407 | - | 0.3 | 1,950 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.11 per share. | 11 May 2021 | 6,220 | 77,407 | - | 0.1 | 684 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 6,220 | 0 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 11 May 2021 | 2,650 | 73,837 | - | 0.3 | 795 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 2,650 | 132,355 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 11 May 2021 | 2,650 | 71,187 | - | 50 | 132,500 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 11 May 2021 | 500 | 77,907 | - | 0.3 | 150 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 500 | 7,793 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 12 Apr 2021 | 5,300 | 76,487 | - | 0.3 | 1,590 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2021 | 5,300 | 135,005 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 59.99 per share. | 12 Apr 2021 | 3,473 | 72,016 | - | 60.0 | 208,345 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 59.10 per share. | 12 Apr 2021 | 998 | 75,489 | - | 59.1 | 58,982 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 61.08 per share. | 12 Apr 2021 | 729 | 71,287 | - | 61.1 | 44,527 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 61.72 per share. | 12 Apr 2021 | 100 | 71,187 | - | 61.7 | 6,172 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.11 per share. | 01 Apr 2021 | 9,996 | 71,187 | - | 0.1 | 1,100 | Common Stock |
| Keros Therapeutics Inc | Jennifer Lachey | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 9,996 | 0 | - | - | Employee Stock Option (right to buy) |